'Auspex' of Chemistry: $25M for Phase III in Huntington's
By Randy Osborne
Friday, November 9, 2012
Is it possible, by tweaking the only molecule approved for movement disorders in Huntington's disease, to come up with a new chemical entity that's safer and dosed less often, thanks to a much longer half-life?
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.